The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

• Status: Completed
• Trial end date: 2016-10-01

Summary

This is an open-label, 2-cycle, multiple-dose, single-sequence study in women of child-bearing potential. The primary objective is to assess the effect of BMS-986142 on the pharmacokinetics (PK) of Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate.

• Phase: Phase 1

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Estradiol; Ethinyl Estradiol; Norethindrone; Norethindrone acetate; Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination; Norinyl